Eli Lilly Stock After Q2 2026: The Guidance Raise Has Two Halves, and Only One Went Up

Eli Lilly reported 48% revenue growth and raised its full-year revenue outlook by $2.5 billion at the midpoint — while simultaneously lowering the top end of its non-GAAP EPS guidance from $37.00 to $36.50. Both facts are in the same press release. Most coverage today will report only the first.

Read the Guidance Raise as Two Separate Numbers

Lilly increased 2026 revenue guidance to $85.0–87.0 billion from $82.0–85.0 billion, but the updated non-GAAP EPS range of $35.50–36.50 is narrower and lower at the top than the prior $35.50–37.00.

The company explained the mechanism plainly: underlying non-GAAP EPS guidance was raised by $2.78 at the midpoint, and that increase was more than offset by $3.03 per share in acquired in-process R&D charges from Q2 business development activity.

Two things follow from this, and they point in opposite directions.

The bearish read: reported full-year earnings will be lower at the top end than management previously indicated, and the tax line got worse too — the non-GAAP effective tax rate rose to 22.2% from 16.5% a year ago, driven by the non-deductibility of those IPR&D charges.

The bullish read, which is the more important one: Lilly includes acquired IPR&D inside its non-GAAP figures. Many peers exclude it. That means the $35.50–36.50 guidance is understating the underlying earnings power of the operating business by roughly $3 per share. Adjust for it and the implied underlying range is closer to $38.50–39.50 — which materially changes any forward P/E you calculate.

Practical takeaway: if you are comparing Lilly's forward multiple to another pharma company's, check whether the peer excludes IPR&D from its adjusted EPS. If it does, you are comparing a conservative number to a flattering one.

Q2 2026 by the Numbers

The quarter beat on every headline line, and the size of the beat was unusual even by recent Lilly standards.

Context for the guidance raise: ahead of the print, Goldman Sachs had framed the size of the raise as the single most important variable for how the stock would trade, seeing room for as much as $1 billion and modelling $86.1 billion for the year. Lilly raised the midpoint by $2.5 billion. Shares rose more than 5% in premarket trading.

The Metric That Decides the Next Two Years

Growth is coming entirely from volume, and realized prices are falling — the press release says so in three separate places.

Look at where "lower realized prices" appears: in the gross margin discussion, where it partially offsets production-cost improvements; in the Mounjaro U.S. line, where 45% growth came despite it; and in the Zepbound commentary, where prescription demand more than made up for a decline in net prices.

That is not a complaint about the quarter — 45% U.S. growth against falling net price is an extraordinary result. But it defines the arithmetic going forward. Revenue growth is (volume growth) minus (net price erosion). Right now volume is winning by an enormous margin. The question for anyone holding this stock into 2027 and 2028 is not whether price erosion continues — in this category, with more entrants arriving, it does — but whether volume growth stays several times larger than it.

Watch the international line as the leading indicator. Mounjaro's international revenue ($5.2 billion) now exceeds its U.S. revenue ($4.8 billion), which means the growth engine is increasingly in markets with different pricing and reimbursement dynamics than the U.S.

What Lilly Bought, and Why the Charge Appeared

The $3.03 IPR&D charge is the accounting cost of an aggressive pipeline-buying quarter. In Q2, Lilly completed acquisitions of Orna Therapeutics, Ajax Therapeutics, Centessa Pharmaceuticals and Kelonia Therapeutics. After quarter end it completed three more acquisitions to build an infectious disease portfolio and agreed to acquire AtaiBeckley. It also committed an additional $4.5 billion to expand Indiana manufacturing.

This is a deliberate capital allocation choice: convert current earnings into future optionality. Whether it was a good choice will not be visible for years, and none of those assets carries near-term revenue. What retail investors should take from it is narrower and immediately useful — when a company charges acquired IPR&D through its adjusted EPS, an acquisition-heavy quarter will look like an earnings miss even when the operating business accelerated. Expect this pattern to recur.

The Pipeline Clock

Retatrutide has cleared five Phase 3 studies, but the BLA submission is planned for Q1 2027 — meaningful revenue is a 2028-and-later event.

Lilly announced positive topline results from TRIUMPH-2 and TRIUMPH-3 on July 23, following TRIUMPH-1 in May, and stated it now has the clinical data package to support global submissions. Analysts have characterized the efficacy profile as setting a new benchmark in the category, above Lilly's own Zepbound. (Clinical detail is outside the scope of this article; consult a physician for anything treatment-related.)

The investor-relevant point is timing, not efficacy. A Q1 2027 filing puts approval, at the earliest, near the end of 2027, followed by a launch and ramp. Anyone underwriting Lilly's current valuation on retatrutide is discounting cash flows that begin in 2028. That is a legitimate thing to do — it is also a long duration for a position, and duration is exactly what a high multiple is most sensitive to.

Nearer-term, Foundayo (orforglipron) is already FDA-approved as an oral option, and its uptake through late 2026 is the more immediate commercial test.

What the Multiple Assumes

At roughly $1,100–1,170 per share against midpoint 2026 non-GAAP EPS guidance of about $36, the stock trades near 31x forward earnings — or closer to 29x if you add back the IPR&D charge.

For a company growing revenue 48% with an 86% gross margin, that is not obviously expensive. For a pharmaceutical company, it is a multiple that assumes the incretin franchise compounds for years without a step-change in competition or reimbursement. Both of those assumptions are reasonable today. Neither is guaranteed, and a stock at this multiple re-rates quickly when one of them is questioned.

What Would Break the Thesis

• Price erosion accelerates faster than volume. The single most likely mechanism, and it is already visible in the disclosures.

• Manufacturing or supply constraints. Lilly is committing billions to capacity precisely because demand has outrun supply; execution here is a real risk, not a formality.

• Reimbursement policy shifts. Coverage decisions by large payers or government programs can change the net price picture in a single announcement.

• Competitive entry. Novo Nordisk remains the primary rival, with Roche, AstraZeneca and others developing obesity assets. Being first is not the same as staying alone.

• The multiple itself. At roughly 31x forward earnings, a slower-than-expected quarter does not need to be bad to cause a large drawdown — it only needs to be less good.

Frequently Asked Questions

Did Eli Lilly raise or lower guidance in Q2 2026?
Both, on different lines. Full-year revenue guidance went up to $85.0–87.0 billion from $82.0–85.0 billion. Non-GAAP EPS guidance was narrowed to $35.50–36.50 from $35.50–37.00 — the underlying business raise of $2.78 per share was more than offset by $3.03 per share of acquired IPR&D charges from the quarter's acquisitions.

Why did Eli Lilly's EPS include a $3.03 charge?
Lilly completed four acquisitions during Q2 2026 (Orna, Ajax, Centessa and Kelonia), and it records acquired in-process R&D charges inside both its reported and non-GAAP EPS rather than excluding them. The charges are also largely non-deductible, which pushed the non-GAAP effective tax rate to 22.2% from 16.5% a year earlier.

How much did Mounjaro and Zepbound sell in Q2 2026?
Mounjaro generated $9.9 billion, up 91% year over year, split between $4.8 billion in the U.S. and $5.2 billion internationally. Zepbound generated $4.9 billion in U.S. revenue, up 44%. Both grew on volume, with the company noting lower realized prices in each case.

Is Eli Lilly stock expensive right now?
At recent levels the stock trades near 31x the midpoint of 2026 non-GAAP EPS guidance, or roughly 29x if the IPR&D charge is added back. Whether that is expensive depends on how long you expect 40%-plus revenue growth to persist against rising competition and falling net prices. This is not investment advice.

When could retatrutide contribute to revenue?
Lilly plans to submit a Biologics License Application to the FDA in Q1 2027 after positive results across five Phase 3 studies. Standard review timelines put potential approval near the end of 2027 at the earliest, with meaningful revenue contribution more likely from 2028 onward.